May 10, 2019· Comment from Endocrine Society· FDA-2019-N-1132-0004
Filed on regulations.gov — full text not in the inline record.
FDANonrulemakingFDA-2019-N-1132
The Future of Insulin Biosimilars: Increasing Access and Facilitating the Efficient Development of Biosimilar and Interchangeable Insulin Products; Date for Public Hearing; Request for Comments
RIN
—
Last modified
Jun 25, 2019
Comment window
closed 2615d ago
The Endocrine Society filings
1
Activity
The Endocrine Society filed 1 comment on this docket between May 10, 2019 and May 10, 2019. 5 other organizations filed here. The comment window closed 2615d ago.
What The Endocrine Society filed (1)
Abstract
No abstract recorded.
View on regulations.gov →Co-filers (5)
See everyone who commented →- The Endocrine SocietyTHIS ORG1 filing · confidence 85%
- American Pharmacists Association (APhA)trade assoc.1 filing · confidence 97%
- American Society of Consultant Pharmaciststrade assoc.1 filing · confidence 85%
- Association for Accessible Medicinestrade assoc.1 filing · confidence 97%
- Eli Lilly and Companyunverified attribution1 filing · confidence 70%
- Novartis Services Inc.unverified attribution1 filing · confidence 70%